Sonnet BioTherapeutics Holdings, Inc. (SONN) Stock Analysis & Investment Frameworks
Sonnet BioTherapeutics Holdings, Inc. (SONN) stock analysis on Invetso. Review Sonnet BioTherapeutics Holdings, Inc.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
Sonnet BioTherapeutics Holdings, Inc. Company Overview
- Exchange: NASDAQ Capital Market
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
Sonnet BioTherapeutics Holdings, Inc. Key Financial Metrics
- Market Cap: $8.43M
- Revenue: $1.00M
- ROE: -244.43%
- ROIC: -77.63%
- Dividend Yield: N/A
About Sonnet BioTherapeutics Holdings, Inc.
Sonnet BioTherapeutics Holdings, Inc., a biotechnology company based in Princeton, New Jersey, operates in the clinical stage with a primary focus on oncology. The firm is dedicated to developing novel platforms for creating biologic medicines that can exhibit either singular or dual therapeutic mechanisms. Central to their strategy is a proprietary fully human albumin binding technology. This innovative system employs human single-chain antibody fragments specifically engineered to bind to human serum albumin, leveraging it for enhanced delivery and transport to target tissues. Their leading therapeutic candidate, SON-1010, is a fully human variant of interleukin 12, currently being advanced for the treatment of non-small cell lung cancer and cancers affecting the head and neck. Additionally, Sonnet is progressing SON-080, another fully human interleukin 6 formulation, intended to address both chemotherapy-induced and diabetic peripheral neuropathy. The company also maintains a licensing agreement with New Life Therapeutics PTE, LTD., for the development and commercialization of pharmaceutical preparations containing a specific recombinant human interleukin 6.